FindTrial
Sign In

LIVTENCITY 200 mg film-coated tablets.

DRUG3 trials

Sponsors

Takeda Development Center Americas Inc., Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Conditions

Allogeneic peripheral hematopoietic stem cell transplantCytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)Cytomegalovirus infectionTransplant patients with high recurrent Epstein-Barr infection

Phase 2

A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
Not yet recruitingCTIS2025-521074-34-00
Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia CellulareAllogeneic peripheral hematopoietic stem cell transplant, Cytomegalovirus infection
Target: 81Updated: 2025-11-17

Phase 3

"Full title (English): A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT) "
Active, not recruitingCTIS2023-508988-73-00
Takeda Development Center Americas Inc.Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)
Start: 2025-10-29Target: 21Updated: 2025-09-18

Phase 4

A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie
Not yet recruitingCTIS2025-524786-25-00
Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaTransplant patients with high recurrent Epstein-Barr infection
Target: 10Updated: 2026-05-13